EZH2, an on-off valve in signal network of tumor cells

Cellular Signalling
Shanshan SunXuan Zhou

Abstract

Enhancer Zeste 2 (EZH2) is a histone methyltransferase catalyzing histone H3K27me3 to mediate gene silence. It is implicated in governing various biological behaviors of human malignancies. In this review, we over-review EZH2 serves as an "on-off valve"--not only as a critical epigenetic repressor, but as a brand-new activator for specific downstream targets as well. Time and space it "switching on-off" depends on the context and its cellular type. Moreover, EZH2 could act as a Tumor-Defender under certain circumstances. Moreover, the "Mutual-Inhibition" relationship between EZH2 and microRNAs is elaborated. In addition, we focus on different functions of phosphorylatied EZH2 in tumor cells. Finally, EZH2 inhibitors are summarized and newly-discovered strategies of targeting-EZH2 treatment are prospected.

References

Jun 23, 2004·Oncogene·Xiaohu TangVarda Rotter
Dec 17, 2005·Nature·Emmanuelle ViréFrançois Fuks
Dec 23, 2006·Development·Leonie Ringrose, Renato Paro
Apr 24, 2008·The Journal of Biological Chemistry·Satoshi FujiiAtsushi Ochiai
Aug 30, 2008·Mutation Research·Jeffrey A Simon, Carol A Lange
Nov 15, 2008·Science·Sooryanarayana VaramballyArul M Chinnaiyan
Aug 12, 2009·Cell Stem Cell·Dennis Van HoofJeroen Krijgsveld
Nov 26, 2009·Cancer Research·Mario-Luca SuvàIvan Stamenkovic
Jul 10, 2010·Science·Miao-Chih TsaiHoward Y Chang
Jan 3, 2012·International Journal of Biological Sciences·Kyung Hyun Yoo, Lothar Hennighausen
Mar 7, 2012·Genes & Development·Jon Mallen-St ClairDafna Bar-Sagi
Mar 21, 2012·Genes & Development·Camille SimonGuy Sauvageau
Aug 29, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Junko KikuchiHirotoshi Dosaka-Akita
Nov 3, 2012·The International Journal of Biochemistry & Cell Biology·Angelo FerraroAlexander Pintzas
Dec 14, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wei QiEn Li
Feb 21, 2013·The Journal of Pathology·Yan-Wei LinJing-Yuan Fang
Apr 30, 2013·The EMBO Journal·Lan WangHaojie Huang
Jun 15, 2013·Cancer Cell·Shaun D Fouse, Joseph F Costello
Jul 10, 2013·Proceedings of the National Academy of Sciences of the United States of America·Wendy W Hwang-VersluesWen-Hwa Lee
Aug 13, 2013·Biochemical and Biophysical Research Communications·Ju-Kyung Lee, Keun-Cheol Kim

❮ Previous
Next ❯

Citations

Jan 8, 2019·Journal of Dental Research·M V Bais
Dec 30, 2017·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Julie C NienstedtChristina Pflug
Oct 28, 2018·Journal of Neuroinflammation·Sunny MalhotraManuel Comabella
Mar 16, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shanshan SunXuan Zhou
Jun 1, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Li ZhouBo Ge

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cadherins and Catenins

Cadherins (named for "calcium-dependent adhesion") are a type of cell adhesion molecule (CAM) that is important in the formation of adherens junctions to bind cells with each other. Catenins are a family of proteins found in complexes with cadherin cell adhesion molecules of animal cells: alpha-catenin can bind to β-catenin and can also bind actin. β-catenin binds the cytoplasmic domain of some cadherins. Discover the latest research on cadherins and catenins here.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.